相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021
Wiktoria Budziar et al.
PLOS ONE (2022)
Two Doses of BNT162b2 mRNA Vaccine in Patients after Hematopoietic Stem Cell Transplantation: Humoral Response and Serological Conversion Predictors
Maciej Majcherek et al.
CANCERS (2022)
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Ohad Benjamini et al.
HAEMATOLOGICA (2022)
Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients
Cristina Bagacean et al.
BLOOD (2021)
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2021)
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Heinz Ludwig et al.
LANCET HAEMATOLOGY (2021)
BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype
Gisella Guerrera et al.
SCIENCE IMMUNOLOGY (2021)
Antibodies and Vaccines Target RBD of SARS-CoV-2
Long Min et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2021)
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma
Irit Avivi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
Oliver Van Oekelen et al.
CANCER CELL (2021)
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report
Antonio Cuneo et al.
HEMATOLOGICAL ONCOLOGY (2021)
Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia
Tamar Tadmor et al.
LEUKEMIA (2021)
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma
Samuel D. Stampfer et al.
LEUKEMIA (2021)
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
Erin M. Bange et al.
NATURE MEDICINE (2021)
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
Florent Malard et al.
BLOOD CANCER JOURNAL (2021)
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia
H. Parry et al.
BLOOD CANCER JOURNAL (2021)
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies
David J. Chung et al.
BLOOD CANCER DISCOVERY (2021)
Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV
Vargab Baruah et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Anthony R. Mato et al.
BLOOD (2020)
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
Lydia Scarfo et al.
LEUKEMIA (2020)
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
Ajai Chari et al.
BLOOD (2020)
Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
Camille Guillerey et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Perturbation of the normal immune system in patients with CLL
Francesco Forconi et al.
BLOOD (2015)
Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses
Kimberly Noonan et al.
CLINICAL CANCER RESEARCH (2012)